文献速递主动脉疾病

Advanta V12或iCAST桥接支架用于开窗与分支主动脉腔内修复术结局的系统评价与Meta分析

Systematic Review and Meta-analysis of Outcomes of the Advanta V12 or iCAST Bridging Stent Graft Used for Fenestrated and Branched Endovascular Aortic Repair.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-01-13

该系统评价与Meta分析检索MEDLINE、Embase和Cochrane数据库(截至2024年4月15日),纳入10项回顾性研究(7525个目标血管,其中3890个使用Advanta V12/iCAST桥接),评估该桥接支架在开窗与分支主动脉腔内修复术中的表现。结果显示目标血管免于不稳定、狭窄和/或闭塞、Ic和IIIc型内漏及再干预的比例均较高,作者结论认为该桥接支架表现良好。

要点

  • 纳入10项回顾性研究,共7525个目标血管,其中3890个使用Advanta V12/iCAST桥接。
  • 免于不稳定为94%(95%CI 91-96%),GRADE证据质量极低。
  • 免于再干预为95%(95%CI 92-97%),开窗与分支间表现相似。

核心结论

  • Advanta V12/iCAST桥接支架在目标血管免于不稳定、狭窄和/或闭塞及内漏方面表现出较高比例。
  • 免于再干预的比例为95%,在开窗与分支中均较高。

研究设计与样本

  • 系统评价与Meta分析,遵循PRISMA指南和PICO模型,方案注册于PROSPERO(CRD42024556603)。
  • 检索MEDLINE、Embase(通过Ovid)和Cochrane数据库,截至2024年4月15日。
  • 纳入2010至2024年报告的随机对照试验和观察性研究,最终纳入10项回顾性研究。
  • 共7525个目标血管,其中3890个目标血管使用Advanta V12/iCAST桥接。
  • 使用ROBINS-I评估偏倚风险,使用GRADE评估证据质量。

主要发现

  • 平均随访24.3个月(95%CI 23.9-24.7)。
  • 免于不稳定为94%(95%CI 91-96%;p<.010;I²=91%;GRADE证据质量极低)。
  • 免于狭窄和/或闭塞为97%(95%CI 96-98%;p=.070;I²=44%;GRADE证据质量低)。
  • 免于Ic和IIIc型内漏为97%(95%CI 94-98%;p<.010;I²=81%;GRADE证据质量极低)。
  • 免于目标血管再干预为95%(95%CI 92-97%;p<.010;I²=85%;GRADE证据质量极低)。

关键数值与推荐

  • 4项研究提供了Advanta V12/iCAST在开窗中的可提取数据,4项提供了在分支中的数据。
  • 免于不稳定在开窗与分支间无差异(p=.47)。
  • 免于狭窄和/或闭塞在开窗与分支间无差异(p=.36)。
  • 免于Ic和IIIc型内漏在开窗与分支间无差异(p=.90)。
  • 免于再干预在开窗中为93%(95%CI 87-96%;p<.010;I²=90%),在分支中为95%(95%CI 91-97%;p=.060;I²=64%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 根据ROBINS-I,没有研究为高质量。
  • 免于不稳定的GRADE证据质量极低。
  • 免于狭窄和/或闭塞的GRADE证据质量低。
  • 免于Ic和IIIc型内漏的GRADE证据质量极低。
  • 免于目标血管再干预的GRADE证据质量极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Half of re-interventions after fenestrated and branched endovascular aortic repair (FB-EVAR) are target vessel related. Regarding bridging stent choice, existing data are controversial. This meta-analysis aimed to evaluate the performance of Advanta V12/iCAST as the bridging stent in FB-EVAR. DATA SOURCES: The English medical literature was searched through MEDLINE, Embase (via Ovid), and Cochrane databases (end date 15 April 2024). REVIEW METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines and PICO (Patient, Intervention, Comparison, Outcome) model were followed. A predefined protocol was registered to PROSPERO (CRD42024556603). Randomised controlled trials and observational studies (2010 - 2024) reporting on Advanta V12/iCAST related target vessel outcomes were eligible. Risk of bias was assessed using ROBINS-I, and evidence quality was assessed via Grading of Recommendations Assessment, Development and Evaluations (GRADE). Primary outcomes were freedom from instability, stenosis and or occlusion, types Ic and IIIc endoleak, and re-intervention of target vessels bridged with the Advanta V12/iCAST. Prevalence and regression meta-analysis were performed. RESULTS: From 1 439 articles, ten retrospective studies (7 525 target vessels; 3 890 target vessels bridged with Advanta V12/iCAST) were included. According to ROBINS-I, no study was of high quality. Mean follow up was 24.3 (95% confidence interval [CI] 23.9 - 24.7) months. Freedom from instability, stenosis and or occlusion, and types Ic and IIIc endoleak were 94% (95% CI 91 - 96%; p < .010; I2 = 91%; GRADE certainty, very low), 97% (95% CI 96 - 98%; p = .070, I2 = 44%; GRADE certainty, low), and 97% (95% CI 94 - 98%; p < .010; I2 = 81%; GRADE certainty, very low), respectively. Freedom from target vessel re-intervention was 95% (95% CI 92 - 97%; p < .010; I2 = 85%; GRADE certainty, very low). Four studies provided extractable data on Advanta V12/iCAST in fenestrations and four in branches. No difference was detected in freedom from instability (p = .47), stenosis and or occlusion (p = .36), and types Ic and IIIc endoleak (p = .90). Freedom from re-intervention was 93% (95% CI 87 - 96%; p < .010; I2 = 90%) in fenestrations and 95% (95% CI 91 - 97%; p = .060, I2 = 64%) in branches. CONCLUSION: The Advanta V12/iCAST bridging stent showed high freedom from target vessel instability, stenosis and or occlusion, and endoleak. Freedom from re-intervention was 95%, being similarly high in fenestrations and branches.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Nana P, Dakis K, Brodis A, et al. Systematic Review and Meta-analysis of Outcomes of the Advanta V12 or iCAST Bridging Stent Graft Used for Fenestrated and Branched Endovascular Aortic Repair. Eur J Vasc Endovasc Surg. 2025. PMID: 39814313. doi:10.1016/j.ejvs.2025.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。